Britain’s GSK to buy Affinivax for up to $3.3 bln in vaccines push

Britain’s GSK to buy Affinivax for up to $3.3 bln in vaccines push

GSK said on Tuesday it would pay up to $3.3 billion to acquire privately held biopharmaceutical firm Affinivax to bolster its vaccine pipeline, a key area of focus as the British drugmaker prepares to separate its consumer unit. GSK, the world’s largest vaccine maker by sales, has been under pressure to shore up its pipeline. … Read more